Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
Primary completion pushed from Nov 2025 to Nov 2031
Also in this update: Primary endpoint(s) modified; Enrollment increased: 5 → 60 participants
University of Colorado, DenverPhase 1 NCT06414096 Registry history of NCT06414096 on ClinicalTrials.gov (opens the registry)